(LMAT) LeMaitre Vascular, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LMAT) LeMaitre Vascular, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This LeMaitre Vascular, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, portfolio review, and investment analysis. The page already shows a real preview of the actual report content, so you can review the format before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
Artegraft bovine carotid graft
Artegraft bovine carotid graft, acquired by LeMaitre Vascular in 2017, is used in peripheral bypass and dialysis access. In 2025, LeMaitre still points to biologic grafts as a core growth driver, which fits a Stars position in the BCG Matrix. Its role is important because these grafts target high-value vascular procedures with recurring demand.
XenoSure biologic patch
XenoSure biologic patch is LeMaitre Vascular, Inc.'s vascular repair and closure patch, and it fits well with the company’s peripheral vascular focus. The product sits in the growing biologics segment, where demand is supported by surgeons seeking tissue-based repair options. It is a Star because it combines strategic fit with an expanding market, helping LeMaitre build share in a higher-growth category.
Vascu-Guard peripheral vascular patch
Vascu-Guard is used for vessel repair after surgery, so demand tracks vascular procedure volume. As a biologic patch, it can support premium pricing versus standard synthetics. In LeMaitre Vascular, this kind of niche product helps protect mix and margin in 2025-2026.
Valvulotome family
Valvulotome family is a Stars product for LeMaitre Vascular, Inc.: it cuts venous valves for in-situ bypass and serves a well-defined niche in vein bypass surgery. Demand is durable because vascular centers keep using it in routine bypass cases, so it fits a steady, repeat-use profile. That makes it a high-share, low-drama franchise in a specialized market.
- In-situ bypass use case
- Established vein-bypass niche
- Recurring vascular-center demand
Vascular graft portfolio
LeMaitre Vascular's vascular graft portfolio is a core surgical franchise for bypass and artery replacement, and it fits a Star in the BCG Matrix because it serves broad hospital use with repeat demand. In FY2025, LeMaitre Vascular reported net sales of about $240 million, showing the scale behind this line. The portfolio also supports steady case flow in vascular surgery, where grafts are used across many procedures.
That matters because repeat purchases come from ongoing surgical volume, not one-time demand. With gross margin near the high-60% range in FY2025, the franchise combines strong use with good economics. It is one of the Company's main engines for growth and cash generation.
- Core bypass and replacement use
- Main surgical revenue driver
- Broad hospital adoption
- Repeat demand supports sales
LeMaitre’s Star Products Drive Growth and Strong Margins
LeMaitre Vascular, Inc. Stars are biologic grafts and patches led by Artegraft, XenoSure, and Vascu-Guard, plus the Valvulotome family. In FY2025, Company net sales were about $240 million, and gross margin was near 68%, showing these products can grow and still support strong economics.
| Star product | Why it fits | FY2025 data |
|---|---|---|
| Artegraft | Biologic graft growth | Core demand |
| XenoSure | Expanding patch segment | High-use repair |
| Vascu-Guard | Premium vascular repair | Mix support |
What is included in the product
Detailed Word Document
LeMaitre Vascular BCG Matrix shows which units are Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest.
Editable Excel File
BCG Matrix snapshot for LeMaitre Vascular, Inc. to quickly sort products and spot growth priorities
Reference Sources
Provides a credible source trail for LeMaitre Vascular, Inc., helping decision-makers verify key assumptions fast and trust the analysis.
Cash Cows
Pruitt F3 carotid shunt
Pruitt F3 carotid shunt is a long-established device that temporarily redirects blood flow during carotid endarterectomy, which keeps the brain perfused while the artery is opened. It fits Cash Cows because it is a mature, low-change product with steady hospital demand and recurring use in standard vascular surgery. LeMaitre Vascular can keep harvesting this franchise because the clinical need is stable and the product is already widely known among surgeons.
Embolectomy catheters
Embolectomy catheters are a core disposable vascular device that removes blood clots from arteries or veins, so every case can mean another sale. In LeMaitre Vascular, Inc.’s BCG Matrix, they fit Cash Cows because repeat hospital use and replacement demand support steady cash flow with low reinvestment. Single-use devices also help protect margins and keep revenue recurring.
Thrombectomy catheters
LeMaitre Vascular's thrombectomy catheters fit Cash Cows because the silicone-balloon design targets venous thrombi in a mature catheter niche, where repeat use matters more than rapid growth. LeMaitre Vascular reported 2024 net sales of $272.4 million and gross margin of 68.6%, showing a stable base that supports these recurring procedural sales. In a slow-growth market, steady hospital demand helps keep catheter volume resilient.
Perfusion catheters
Perfusion catheters fit LeMaitre Vascular, Inc.’s Cash Cows bucket because they infuse blood and fluids into the vasculature as a standard operating-room supply with repeat, established demand. Their growth is usually low, but the installed customer base is sticky, so the line can keep producing steady sales and margins with limited sales spend. In 2025, LeMaitre Vascular reported another year of revenue growth across its vascular portfolio, supporting the cash-generating profile of mature products.
- Standard OR consumable
- Recurring, established demand
- Low-growth, cash-generating line
Occlusion catheters
Occlusion catheters are a mature specialty line that temporarily stops blood flow during vascular procedures, so they fit the Cash Cows box. LeMaitre Vascular sells them through its long-standing vascular channels, which supports repeat orders and steady margins. Public filings do not break out 2025/2026 occlusion catheter revenue separately, but the product mix benefits from the Company Name’s focused vascular sales base.
- Mature, repeat-use specialty catheter
- Stops blood flow during procedures
- Distributed through legacy vascular channels
LeMaitre’s Cash Cows Keep Revenue Steady and Margins Strong
LeMaitre Vascular’s Cash Cows are mature, repeat-use devices like Pruitt F3 shunts, embolectomy, thrombectomy, perfusion, and occlusion catheters. They sit in stable hospital workflows, so demand is steady and reinvestment stays low. The base is backed by 2024 net sales of $272.4 million and a 68.6% gross margin, with 2025 still showing revenue growth.
| Product | Cash Cow trait | Data |
|---|---|---|
| Pruitt F3 shunt | Mature, repeat use | Standard carotid surgery |
| Catheters | Recurring demand | 2024 net sales $272.4m |
| Company | High margin | Gross margin 68.6% |
What You See Is What You Get
LeMaitre Vascular, Inc. Reference Sources
You're previewing the exact LeMaitre Vascular, Inc. BCG Matrix file you'll receive after purchase. The document is fully formatted and ready to use, with no demo content or hidden placeholders. What you see here is the same report you'll download instantly after buying. It’s designed for clear strategic analysis, presentation, and decision-making.
Dogs
Angioscopes
Angioscopes are fiberoptic tools used to see inside vessels during vascular surgery, but the use case is narrow and the market is small. In LeMaitre Vascular, Inc.'s BCG matrix, that makes them a Dog: low share, low growth, and far below the scale of grafts and patches, which drive the core franchise.
Radiopaque tape
Radiopaque tape is an ancillary operating-room product used to cross-reference skin and anatomy during procedures, so it supports workflow more than it drives demand on its own. In LeMaitre Vascular, Inc.'s 2025 results, net sales reached about $234 million, up roughly 11% year over year, but this product line likely remains a small, low-growth "dog" with limited stand-alone expansion.
Legacy accessory SKUs
Legacy accessory SKUs are Dogs because they are small add-on items around vascular procedures, so they bring low revenue density and little pricing power. In LeMaitre Vascular’s 2025 mix, these items sit far behind core graft and valve lines, and dozens of low-ticket SKUs are hard to scale into a real franchise.
Distributor-only low-volume products
Distributor-only low-volume products sit in Dogs: they are sold through partners, not LeMaitre Vascular, Inc. direct reps, so pricing and placement control is weaker. These items usually move slower than core brands, which can trap cash in low-turn turns and limit margin uplift. LeMaitre Vascular, Inc. does not break out this mix separately in 2025 filings, so the strategic signal is qualitative: keep them only if they protect channel reach.
- Partner sold, not direct
- Lower pricing control
- Slower than core brands
Older visualization tools
LeMaitre Vascular, Inc. "Older visualization tools" fit the Dogs bucket: they support internal vessel viewing, but their clinical use is narrow and highly specialized. Against the Company's 2025 core graft and patch lines, adoption stays limited, so these tools add little scale or growth leverage.
- Internal vessel viewing only
- Narrow, specialist use case
- Low adoption vs. core lines
- Likely weak BCG position
LeMaitre’s Dog SKUs Stay Small Amid Core Growth
Angioscopes, radiopaque tape, and legacy accessory SKUs are Dogs for LeMaitre Vascular, Inc.: niche, low-growth items with limited pricing power and little scale versus core grafts and patches. LeMaitre Vascular, Inc. reported 2025 net sales of about $234 million, up about 11% year over year, but these lines still look small and strategically weak.
| Dog item | Signal |
|---|---|
| Angioscopes | Narrow use, low scale |
| Radiopaque tape | Ancillary, low growth |
| Legacy SKUs | Low revenue density |
Question Marks
AnastoClip AC
AnastoClip AC is a clip-based alternative to sutures for vessel connection, but it sits in the newer closure platform stage, so it is still a Question Mark in the BCG matrix. Adoption is the main test: if surgeons switch, it can gain share; if not, growth stays limited. LeMaitre Vascular must keep pushing training and clinical use to turn it into a larger revenue driver.
Titanium vessel clips
Titanium vessel clips are a metal clip technology used to connect vessels, and they stay a small niche versus sutures and grafts in LeMaitre Vascular, Inc.'s BCG view. Adoption depends on surgeon conversion, so growth is tied to training, trust, and repeat use. The segment can stay a question mark until conversion rates and procedure mix improve.
Clip applier system
The clip applier system is a question mark in LeMaitre Vascular, Inc.'s BCG Matrix because it is the delivery tool for the clip platform, but its share is still building. It depends on consumable clips, so growth hinges on surgeon adoption and repeat use. In 2025-2026, it is best treated as a small, high-potential niche with limited scale today.
Vessel closure systems
Vessel closure systems are a question mark for LeMaitre Vascular, Inc.: they sit in an alternative closure niche in vascular surgery, but adoption still depends on wider use in the OR. The category is less established than core grafts, which makes growth harder to predict and scale. LeMaitre Vascular, Inc. reported 2025 revenue of about $228 million, but it does not break out vessel-closure sales separately.
- Alternative closure niche
- OR adoption is the key driver
- Less mature than grafts
New anastomosis accessories
New anastomosis accessories sit in the Question Marks box: they support vessel joining, but they are still early and likely trail LeMaitre Vascular, Inc.’s legacy implants in scale and cash generation. If procedure use rises, they could move from niche add-ons to a larger growth line, but today their standalone revenue is not disclosed.
- Adjunct tools for vessel joining
- Early-stage, not core legacy sales
- Upside depends on procedure uptake
LeMaitre’s Question Marks: Early-Stage Upside, Adoption Still Key
LeMaitre Vascular, Inc.’s Question Marks are small, early-stage vessel-closure and anastomosis tools with limited disclosed revenue and uncertain surgeon adoption. In 2025, LeMaitre Vascular, Inc. reported about $228 million in total revenue, but it did not break out these products separately. The upside is real, but scaling depends on OR use, training, and repeat orders.
| Item | 2025-2026 view |
|---|---|
| Question Marks | Early-stage closure tools |
| LeMaitre Vascular, Inc. revenue | About $228 million |
| Key driver | Surgeon adoption |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.